Crystalys Therapeutics - Passionate. Dedicated. We improve lives.
crystalystx.com
Actively hiring
Science & Engineering
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
501-1000
employees, estimated range
Backers
2
Xontogeny, Lightstone Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Xontogeny 
Lightstone Ventures Similar startupsby what they do, their industry and backers
Industry Trackers. Follow here for all the latest news about mergers, acquisitions and joint partnerships in the healthcare industry.
Home Products G5 NTM Use Cases Technology Testimonials News & Blog Latest News Blog Company Company Board of Directors Advisory Board…
Meet our team Our Team To Learn More The latest News & Insights News & Insights Talk to BrightNight Contact us Join BrightNight and be a…
MISHA Clinical Results Resources Contact FOR PATIENTS COMPANY CAREERS NEWS moximed About us We are not doing ordinary things here. Our…
Stay up-to-date with DIREK's news and updates. Discover our latest events, product releases, and industry insights in the smart building…
Explore Major League Pickleball for the latest events, standings, and news. Follow your favorite teams and players in exciting matches and…
News
His father suffered from gout in silence. Now a San Diego scientist is bringing the cure home
San Diego company is in the final phase of testing a drug to treat gout, a chronic condition.
Read more
Report
Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug
Crystalys's dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecule that Sobi added to its pipeline through a $950 million acquisition.
Read more
Report
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
Financing led by Frazier Life Sciences with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management,...
Read more
Report
Pro access
Upgrade to see all 9 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.